Scholarly Index
Bruce E. Johnson
Dana-Farber Cancer Institute; 86,439 total citations; 616 total publications; best world rank #12
Dana-Farber Cancer Institute
86,439Total citations
616Total publications
122H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Lung Cancer Research Studies | Lifetime | 12 | US 8 | 99.92 |
| Lung Cancer Treatments and Mutations | Lifetime | 17 | US 12 | 99.93 |
| Neuroendocrine Tumor Research Advances | Lifetime | 39 | US 20 | 99.73 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 58 | US 30 | 99.74 |
| Colorectal Cancer Treatments and Studies | Lifetime | 90 | US 40 | 99.61 |
| Cancer Genomics and Diagnostics | Lifetime | 196 | US 125 | 99.57 |
| Cancer therapeutics and mechanisms | Lifetime | 198 | US 118 | 98.82 |
| HER2/EGFR in Cancer Research | Lifetime | 236 | US 114 | 98.95 |
| Peptidase Inhibition and Analysis | Lifetime | 735 | US 331 | 97.62 |
| Melanoma and MAPK Pathways | Lifetime | 357 | US 191 | 96.36 |
| Cancer Mechanisms and Therapy | Lifetime | 520 | US 223 | 95.00 |
| Chromatin Remodeling and Cancer | Lifetime | 536 | US 254 | 88.78 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 197 | US 78 | 98.69 |
| Cancer Genomics and Diagnostics | 2021-2025 | 692 | US 305 | 95.76 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 521 | US 162 | 93.89 |
| Melanoma and MAPK Pathways | 2021-2025 | 280 | US 94 | 86.77 |